Netupitant/palonosetron

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Netupitant/palonosetron
Combination of
Netupitant NK1 receptor antagonist
Palonosetron 5-HT3 receptor antagonist
Clinical data
Trade names Akynzeo
AHFS/Drugs.com akynzeo
MedlinePlus a614053
License data
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Oral
ATC code
Legal status
Legal status
Identifiers
KEGG

Netupitant/palonosetron (trade name Akynzeo) is a fixed dose combination drug for prevention of acute and delayed chemotherapy-induced nausea and vomiting[1]. It is marketed and distributed by Helsinn Therapeutics. Netupitant is an NK1 receptor antagonist and palonosetron is a 5-HT3 receptor antagonist.[2]

Contraindications[edit]

Netupitant/palonosetron is contraindicated during pregnancy.[3]

Adverse effects[edit]

The most common side effects are headache and constipation. The overall profile of adverse effects is comparable to that of palonosetron (see Palonosetron#Adverse effects); no common adverse effects can be attributed to netupitant.[3]

Interactions[edit]

Pharmacology[edit]

References[edit]

  1. ^ "FDA approves Akynzeo for nausea and vomiting associated with cancer chemotherapy". Food and Drug Administration. October 10, 2014. 
  2. ^ "Akynzeo: Summary of Product Characteristics" (PDF). European Medicines Agency. Retrieved 12 July 2016. 
  3. ^ a b Haberfeld, H, ed. (2015). Austria-Codex (in German). Vienna: Österreichischer Apothekerverlag. Akynzeo 300 mg / 0,5 mg Hartkapseln. 

External links[edit]